Clinical Research Directory
Browse clinical research sites, groups, and studies.
GnRH Agonist Pretreatment in Persistent Chronic Endometritis Undergoing FET
Sponsor: Guoxia Yang
Summary
Women with PCE represent a treatment-resistant phenotype in whom the endometrial inflammatory and immune status remains abnormal despite antibiotic therapy. GnRH agonist pretreatment may be most beneficial in endometrial phenotypes marked by persistent or residual inflammatory impairment rather than in all frozen embryo transfer populations.We therefore conducted a single-center prospective cohort study to investigate whether GnRH-HRT, compared with non-GnRH-based preparations, improve clinical pregnancy and live birth in women with PCE undergoing FET,
Official title: Association of GnRH Agonist Pretreatment With Pregnancy Outcomes in Women With Persistent Chronic Endometritis Undergoing Frozen Embryo Transfer
Key Details
Gender
FEMALE
Age Range
20 Years - 40 Years
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2026-06-01
Completion Date
2028-06-01
Last Updated
2026-06-11
Healthy Volunteers
Not specified
Conditions
Interventions
Conventional estrogen-progesterone artificial cycle for endometrial preparation
No GnRH-a down-regulation. Oral estrogen is initiated directly on early menstrual cycle, followed by progesterone transformation to prepare endometrium for FET in patients with persistent chronic endometritis.
GnRH agonist plus estrogen-progesterone for endometrial preparation
Long-acting GnRH agonist is administered on day 2-3 of menstruation for pituitary down-regulation. After satisfactory hormonal suppression, sequential oral estrogen and progesterone are used to prepare endometrium before frozen embryo transfer in patients with persistent chronic endometritis.